Study results of CTT's Calmare Pain Therapy for CIPN to be presented

May 10 2010

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare^® Pain Therapy Treatment. The presentation will be at the American Society of Clinical Oncology's Annual Meeting on June 8, 2010. Information about the meeting is available at http://chicago2010.asco.org/Home.aspx.

Calmare, which treats chronic neuropathic and oncologic pain, received FDA certification for sales in the US in February 2009. In July 2009, clinical investigators at VCU Massey Cancer Center began the first U.S. independent clinical study, to specifically examine the ability of CTT's Calmare pain therapy treatment to decrease pain associated with CIPN. 

"Our Calmare pain therapy is also in use at the University of Miami Pain Management Center under the direction of Dr. Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. The Paul Carbone Cancer Center at the University of Wisconsin, Madison, is using Calmare as well, under the direction of Dr. Toby Campbell, M.D.," said Aris D. Despo, CTT's Executive VP, Business Development. "Both universities are treating patients, evaluating the efficacy of our Calmare pain therapy in treating debilitating pain."

Calmare is also being used to treat US patients in clinics in Rhode Island, Massachusetts, New York, Virginia and Florida.

"Our 2010 revenues are increasing quarter over quarter from the sales of Calmare in the U.S., Italy, Greece, India and Bangladesh," said John B. Nano, CTT's Chairman, President and CEO. "The Calmare Pain Therapy Treatment has US FDA 510(k) clearance and European Union CE certification, which opened the doors to CTT's current international distribution agreements covering nearly half of the world's population. The Calmare pain therapy is a prime example of our strategy to connect clinical science to patient care."

The non-invasive Calmare pain therapy, which uses the biophysical "Scrambler Therapy" technology developed in Italy by CTT's client, Professor Giuseppe Marineo, was brought to CTT with the assistance of Mr. Giuseppe Belcastro, legal counsel for Professor Marineo. 

CTT's partner, GEOMC Co. Ltd. of Seoul, Korea, has current manufacturing facilities capable of commercially producing 200 pain therapy medical devices per month and the partners have agreed to expand production capacity to an increased production level of 600 units per month to match increased order demand. GEOMC has invested over $3 million for the design, tooling and manufacturing facilities for the Calmare medical device. For more information on the device, visit www.CalmareTT.com.